IL299215A - Prevention of axonal damage through binding of an antibody to amyloid beta 1-42 - Google Patents
Prevention of axonal damage through binding of an antibody to amyloid beta 1-42Info
- Publication number
- IL299215A IL299215A IL299215A IL29921522A IL299215A IL 299215 A IL299215 A IL 299215A IL 299215 A IL299215 A IL 299215A IL 29921522 A IL29921522 A IL 29921522A IL 299215 A IL299215 A IL 299215A
- Authority
- IL
- Israel
- Prior art keywords
- prevention
- antibody binding
- amyloid beta
- axonal damage
- axonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043872P | 2020-06-25 | 2020-06-25 | |
| PCT/EP2021/067536 WO2021260193A1 (en) | 2020-06-25 | 2021-06-25 | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299215A true IL299215A (en) | 2023-02-01 |
Family
ID=76662499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299215A IL299215A (en) | 2020-06-25 | 2021-06-25 | Prevention of axonal damage through binding of an antibody to amyloid beta 1-42 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230287092A1 (enExample) |
| EP (1) | EP4171742A1 (enExample) |
| JP (1) | JP2023531069A (enExample) |
| KR (1) | KR20230026490A (enExample) |
| CN (1) | CN116547299A (enExample) |
| AU (1) | AU2021295605A1 (enExample) |
| BR (1) | BR112022026359A2 (enExample) |
| CA (1) | CA3187785A1 (enExample) |
| IL (1) | IL299215A (enExample) |
| TW (2) | TWI916375B (enExample) |
| WO (1) | WO2021260193A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| WO2024015951A2 (en) * | 2022-07-15 | 2024-01-18 | Seq Biomarque, Llc | Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease |
| CN117624357B (zh) * | 2024-01-26 | 2024-03-22 | 南京诺唯赞医疗科技有限公司 | p-Tau 217特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US151A (en) | 1837-03-25 | Spring-saddle | ||
| US5654A (en) | 1848-06-27 | Door-spring | ||
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| ES2276405T3 (es) | 1995-06-02 | 2007-06-16 | Gilead Sciences, Inc. | Ligandos de oligonucleotidos de alta afinidad a pdgf. |
| US8481277B2 (en) * | 2007-08-21 | 2013-07-09 | Washington University | Alzheimer's diagnosis |
| KR102308915B1 (ko) | 2012-10-15 | 2021-10-06 | 메디뮨 리미티드 | 아밀로이드 베타에 대한 항체 |
| US9958460B2 (en) * | 2013-10-24 | 2018-05-01 | Nanosomix, Inc. | Biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders |
| SI3769781T1 (sl) | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| AR107893A1 (es) * | 2016-03-15 | 2018-06-28 | Astrazeneca Ab | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE |
| JP7177702B2 (ja) * | 2016-05-06 | 2022-11-24 | ナノソミックス・インコーポレイテッド | アルツハイマー病および他の神経変性障害のシナプスタンパク質バイオマーカーおよび鑑別診断 |
| JP6949102B2 (ja) * | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
| US12117456B2 (en) * | 2016-11-10 | 2024-10-15 | Brain Biomarker Solutions In Gothenburg Ab | Methods for detecting an individual as being at risk of developing a neurodegenerative disease |
| CN113853214A (zh) * | 2019-05-21 | 2021-12-28 | Ac免疫有限公司 | 抗Aβ疫苗治疗 |
-
2021
- 2021-06-25 TW TW110123285A patent/TWI916375B/zh active
- 2021-06-25 BR BR112022026359A patent/BR112022026359A2/pt unknown
- 2021-06-25 EP EP21735716.9A patent/EP4171742A1/en active Pending
- 2021-06-25 IL IL299215A patent/IL299215A/en unknown
- 2021-06-25 CA CA3187785A patent/CA3187785A1/en active Pending
- 2021-06-25 CN CN202180052963.4A patent/CN116547299A/zh active Pending
- 2021-06-25 AU AU2021295605A patent/AU2021295605A1/en active Pending
- 2021-06-25 TW TW115103567A patent/TW202619748A/zh unknown
- 2021-06-25 WO PCT/EP2021/067536 patent/WO2021260193A1/en not_active Ceased
- 2021-06-25 KR KR1020237002535A patent/KR20230026490A/ko active Pending
- 2021-06-25 JP JP2022580122A patent/JP2023531069A/ja active Pending
- 2021-06-25 US US18/011,965 patent/US20230287092A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202619748A (zh) | 2026-05-16 |
| BR112022026359A2 (pt) | 2023-01-17 |
| KR20230026490A (ko) | 2023-02-24 |
| TW202216188A (zh) | 2022-05-01 |
| US20230287092A1 (en) | 2023-09-14 |
| AU2021295605A1 (en) | 2023-02-16 |
| CN116547299A (zh) | 2023-08-04 |
| CA3187785A1 (en) | 2021-12-30 |
| EP4171742A1 (en) | 2023-05-03 |
| TWI916375B (zh) | 2026-03-01 |
| WO2021260193A1 (en) | 2021-12-30 |
| JP2023531069A (ja) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287613A (en) | Antibodies that bind gprc5d | |
| ZA202306180B (en) | Anti-n3pglu amyloid beta antibodies and uses thereof | |
| IL291487A (en) | Antibodies that bind to vista at acidic ph | |
| HK40090002A (en) | Prevention of axonal damage using antibody binding to amyloid beta 1-42 | |
| IL320221A (en) | Strained bicyclo-nonanes | |
| CA221658S (en) | Caliper cover | |
| CA229189S (en) | Watch | |
| CA229685S (en) | Watch | |
| CA226878S (en) | Watch | |
| CA225503S (en) | Watch | |
| CA225502S (en) | Watch | |
| CA225288S (en) | Watch | |
| CA225289S (en) | Watch | |
| CA225255S (en) | Watch | |
| CA225275S (en) | Watch | |
| CA225256S (en) | Watch | |
| CA226475S (en) | Watch | |
| CA224689S (en) | Watch | |
| CA223196S (en) | Watch | |
| CA226375S (en) | Watch | |
| CA220616S (en) | Watch | |
| CA221283S (en) | Watch | |
| CA217931S (en) | Watch | |
| CA231152S (en) | Watch | |
| CA217706S (en) | Watch |